Participated · Series B · Aug 2026

InduPro uses a proprietary proximity-guided platform to map spatial organization of proteins on the cell surface and discover selective co-target pairs for therapeutic development. Its lead program, IDP-001, is a potential first-in-class proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA-E1). IDP-001 was designed to enhance tumor selectivity, target internalization, and antitumor efficacy while aiming to preserve tolerability, and the first patient has been dosed in its Phase 1 study. The Phase 1 trial is enrolling adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors to evaluate safety, pharmacokinetics and preliminary antitumor activity. Beyond ADCs, InduPro is developing bispecific antibodies including antibody-drug conjugates and T-cell engagers to build a pipeline of first- and best-in-class programs. The company operates out of Seattle and Cambridge, Mass., and is advancing both clinical and preclinical programs supported by venture and strategic pharma investors.

Participated · Series C · Apr 2026

Adcendo is advancing a pipeline of first- and potential best-in-class antibody-drug conjugates, integrating novel targets and optimized linker-payload combinations. The company is progressing three ADC programs: ADCE-T02 (Tissue Factor) in a Phase I Tiffany-01 cohort expansion across multiple solid tumors, ADCE-D01 (uPARAP) in Phase 1 dose escalation and expansion for soft tissue sarcoma and other mesenchymal cancers, and ADCE-B05 (undisclosed target) in preclinical evaluation and planned dose escalation in squamous cell carcinomas. Founded in 2017, Adcendo is headquartered in Copenhagen with operations in Boston, Massachusetts, and is led by a team with extensive ADC development and commercialization experience. The recent $75 million Series C financing is intended to fund the programs through upcoming clinical milestones and data readouts. No revenue or other operating metrics were disclosed in the provided articles.

Participated · Series A · Mar 2026

Poplar Therapeutics, incorporated in 2024 and based in Cambridge, Massachusetts, is focused on creating a new class of anti-IgE therapies that aim to rapidly drive IgE levels toward zero. Its lead candidate, PHB-050, employs a triple-action mechanism to block IgE binding to mast cells, quickly clear circulating IgE, and inhibit further IgE production. The drug is now in a Phase 1 clinical trial targeting food allergy, with data expected to demonstrate safety, pharmacokinetics, and speed of IgE reduction. Management plans to use forthcoming data to guide Phase 2 studies across multiple atopic conditions, including asthma and atopic dermatitis. Poplar estimates that more than seven million patients with atopic diseases have high IgE levels, half of whom with food allergy are poorly served by existing therapies. The company’s total Series A financing now stands at $95 million, providing resources to advance PHB-050 through at least Phase 2 trials.

Participated · Series B · Dec 2025

Protego Biopharma engineers first-in-class pharmacological chaperones that stabilize misfolded proteins, preventing toxic amyloid accumulation at the root of systemic amyloid diseases. Its lead candidate, PROT-001, targets immunoglobulin light chains and is being advanced toward a pivotal trial for AL amyloidosis, a rare and often fatal condition with limited treatment options. The company’s platform, grounded in human genetics and protein-folding biology, positions it to address a broad spectrum of protein misfolding disorders beyond AL amyloidosis. Protego’s approach aims to deliver disease-modifying rather than symptomatic therapies, representing a potential paradigm shift in this field. Backed by a syndicate of blue-chip life-science investors, the company is now well capitalized following its Series B raise. Although still pre-revenue, Protego benefits from renewed investor confidence and plans to use the new capital primarily for clinical development and regulatory activities related to PROT-001.

Participated · Series A · Jun 2025

Antares Therapeutics applies a proprietary covalent discovery engine—including proprietary screening libraries, chemoproteomics, structure‑guided computational chemistry and machine‑learning tools—to identify challenging, high‑value oncology targets. The company will lead discovery work on a limited set of historically undruggable targets under a collaboration with Novartis while continuing to advance its owned and partnered portfolio of precision cancer and other serious‑disease medicines. Financially, the collaboration provided a $105 million upfront payment and the potential for up to $1.8 billion in additional milestone payments and tiered royalties if programs progress and commercialize. The partnership is intended to pair Antares’ discovery capabilities with Novartis’ development and global commercialization resources to accelerate translation of its science into therapies.